Article Versions Notes

Terpos E, Ntanasis-Stathopoulos I, Kastritis E, Hatjiharissi E, Katodritou E, Eleutherakis-Papaiakovou E, Verrou E, Gavriatopoulou M, Leonidakis A, Manousou K, et al. Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”. Cancers. 2022; 14(11):2768. https://doi.org/10.3390/cancers14112768

Terpos, Evangelos, Ioannis Ntanasis-Stathopoulos, Efstathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, Evangelos Eleutherakis-Papaiakovou, Evgenia Verrou, Maria Gavriatopoulou, Alexandros Leonidakis, Kyriaki Manousou, and et al. 2022. "Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”" Cancers 14, no. 11: 2768. https://doi.org/10.3390/cancers14112768

Terpos, E., Ntanasis-Stathopoulos, I., Kastritis, E., Hatjiharissi, E., Katodritou, E., Eleutherakis-Papaiakovou, E., Verrou, E., Gavriatopoulou, M., Leonidakis, A., Manousou, K., Delimpasi, S., Malandrakis, P., Kyrtsonis, M.-C., Papaioannou, M., Symeonidis, A., & Dimopoulos, M.-A. (2022). Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”. Cancers, 14(11), 2768. https://doi.org/10.3390/cancers14112768